# Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)

> **NCT01031901** · PHASE1 · COMPLETED · sponsor: **The University of Texas Health Science Center, Houston** · enrollment: 52 (actual)

## Conditions studied

- Tuberous Sclerosis
- Neurofibromatoses
- Angiofibroma
- Neurofibroma

## Interventions

- **DRUG:** Skincerity
- **DRUG:** Skincerity plus sirolimus/rapamycin
- **DRUG:** Skinercity plus sirolimus/rapamycin

## Key facts

- **NCT ID:** NCT01031901
- **Lead sponsor:** The University of Texas Health Science Center, Houston
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2011-02
- **Final completion:** 2011-06
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2012-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01031901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01031901, "Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01031901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*